1-(1H-indol-5-yl)-N,N-dimethylmethanamine | 857776-12-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(1H-indol-5-yl)-N,N-dimethylmethanamine
• 英文别名: [(1H-indol-5-yl)methyl]dimethylamine
• CAS: 857776-12-6
• 化学式: C₁₁H₁₄N₂
• 分子量: 174.246
• InChiKey: DWLHRRNZBOFOJP-UHFFFAOYSA-N

物化性质

• 沸点：
  293.9±15.0 °C(Predicted)
• 密度：
  1.099±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(1H-indol-5-yl)-N,N-dimethylmethanamine 、 3,4,5-三甲氧基苯甲酸酐 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 以59%的产率得到5-(N,N-dimethylaminomethyl)-1-(3',4',5'-trimethoxybenzoyl)indole
  参考文献：
  名称：

  Discovery of 4-Amino and 4-Hydroxy-1-aroylindoles as Potent Tubulin Polymerization Inhibitors

  摘要：

  1-Aroylindoline, 1-aroyl-1,2,3,4-tetrahydroquinoline, and 1-aroylindole derivatives were synthesized and evaluated for anticancer activity. The 4-amino and 4-hydroxy-1-aroylindoles 26 and 27 with IC(50) Of 0.9 and 0.6 mu M, respectively, exhibited antitubulin activity superior or comparable to that of colchicine and combretastatin A-4. They also showed antiproliferative activity with IC(50) of 0.3-5.4 nM in a set of human cancer cell lines.

  DOI：

  10.1021/jm800150d
• 作为产物：
  描述：

  5-吲哚甲醛 、 盐酸二甲胺 在 sodium cyanoborohydride 、 三乙胺 作用下， 以 乙醇 为溶剂， 生成 1-(1H-indol-5-yl)-N,N-dimethylmethanamine
  参考文献：
  名称：

  Discovery of 4-Amino and 4-Hydroxy-1-aroylindoles as Potent Tubulin Polymerization Inhibitors

  摘要：

  1-Aroylindoline, 1-aroyl-1,2,3,4-tetrahydroquinoline, and 1-aroylindole derivatives were synthesized and evaluated for anticancer activity. The 4-amino and 4-hydroxy-1-aroylindoles 26 and 27 with IC(50) Of 0.9 and 0.6 mu M, respectively, exhibited antitubulin activity superior or comparable to that of colchicine and combretastatin A-4. They also showed antiproliferative activity with IC(50) of 0.3-5.4 nM in a set of human cancer cell lines.

  DOI：

  10.1021/jm800150d

文献信息

• VIRAL REPLICATION INHIBITORS
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D

  公开号：US20140213586A1

  公开（公告）日：2014-07-31

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新化合物，使用这些新化合物预防或治疗动物的病毒感染的方法，以及这些新化合物的药物用途，更好地用于治疗或预防病毒感染，特别是RNA病毒感染，更特别是属于黄病毒科的病毒感染，更进一步地是登革热病毒感染。本发明还涉及新化合物的药物组成物或复合制剂，以及用于预防或治疗病毒感染的药物组成物或制剂。本发明还涉及化合物的制备方法。
• Sodium hypophosphite mediated reductive amination of carbonyl compounds with <i>N</i>,<i>N</i>-dialkylformamides
  作者：Artemy R. Fatkulin、Vasily Korochantsev、Oleg I. Afanasyev、Evgeniya Podyacheva、Olga Chusova、Dmitry V. Muratov、Maria I. Godovikova、Sergei Semenov、Denis Chusov

  DOI：10.1039/d3nj00728f

  日期：——

  Herein we report a transition-metal- and acid-free protocol for the reductive amination of carbonyl compounds with DMF using a substoichiometric amount of NaH2PO2·H2O. A set of various N,N-dimethylamines were obtained in moderate to excellent yields without chromatographic purification. The general trends and limitations of the method with different formamides as sources of dialkyl-fragments were explored

  在此，我们报告了一种使用亚化学计量的 NaH 2 PO 2 · H 2 O的 DMF 对羰基化合物进行还原胺化的无过渡金属和无酸方案。无需色谱纯化即可获得出色的收率。探讨了使用不同甲酰胺作为二烷基片段来源的方法的一般趋势和局限性。
• Viral replication inhibitors
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. Leuven R&D

  公开号：US10550123B2

  公开（公告）日：2020-02-04

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新型化合物、使用这些新型化合物预防或治疗动物病毒感染的方法以及用作药物的所述新型化合物，更优选用作治疗或预防病毒感染的药物，特别是 RNA 病毒感染，更特别是属于黄病毒科的病毒感染，更特别是登革热病毒感染。本发明还涉及新型化合物的药物组合物或组合制剂、用作药物的组合物或制剂，更优选用于预防或治疗病毒感染。本发明还涉及化合物的制备工艺。
• US7342016B2
  申请人：——

  公开号：US7342016B2

  公开（公告）日：2008-03-11